Explore
Validate
Learn
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB2037-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human Complement Component C5/C5a Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human Complement Component C5/C5a in ELISAs and Western blots. In sandwich immunoassays, detects human Complement Component C5a by itself or in the context of Complement Component C5. In Western blots, this antibody does not cross-react with recombinant human Complement Component C2, recombinant mouse (rm) Complement Component C3d, or rmComplement Component C5a.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
P01031- Isotype
- IgG
- Antibody clone number
- 295003
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Attenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb.
Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies.
C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome.
Georgoutsou-Spyridonos M, Ricklin D, Pratsinis H, Perivolioti E, Pirmettis I, Garcia BL, Geisbrecht BV, Foukas PG, Lambris JD, Mastellos DC, Sfyroera G
Journal of immunology (Baltimore, Md. : 1950) 2015 Oct 15;195(8):3946-58
Journal of immunology (Baltimore, Md. : 1950) 2015 Oct 15;195(8):3946-58
Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies.
Ramadass M, Ghebrehiwet B, Smith RJ, Kew RR
Journal of immunology (Baltimore, Md. : 1950) 2014 Feb 1;192(3):1220-30
Journal of immunology (Baltimore, Md. : 1950) 2014 Feb 1;192(3):1220-30
C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome.
Kambas K, Markiewski MM, Pneumatikos IA, Rafail SS, Theodorou V, Konstantonis D, Kourtzelis I, Doumas MN, Magotti P, Deangelis RA, Lambris JD, Ritis KD
Journal of immunology (Baltimore, Md. : 1950) 2008 Jun 1;180(11):7368-75
Journal of immunology (Baltimore, Md. : 1950) 2008 Jun 1;180(11):7368-75
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- N-Acetyl-beta-D-Glucosamini-dase Release Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody. Recombinant Human Complement Component C5a (Catalog # 2037-C5) induces N-acetyl-beta-D-glucosaminidase release in the the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line in a dose-dependent manner (orange line). N-Acetyl-beta-D-Glucosamin-idase Release elicited by Recombinant Human Complement Component C5a (10 ng/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-Human Complement Component C5a Monoclonal Antibody (Catalog # MAB2037). The ND50 is typically 0.04-0.12 µg/mL in the presence of cytochalasin-B.
